vs
Pacira BioSciences, Inc.（PCRX）与Riley Exploration Permian, Inc.（REPX）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Riley Exploration Permian, Inc.的1.6倍（$177.4M vs $113.9M），Pacira BioSciences, Inc.净利率更高（1.6% vs -61.8%，领先63.5%），Riley Exploration Permian, Inc.同比增速更快（11.2% vs 5.0%），过去两年Riley Exploration Permian, Inc.的营收复合增速更高（3.9% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Riley Exploration Permian, Inc.是一家独立能源企业，专注于美国得克萨斯州与新墨西哥州境内的二叠纪盆地，开展原油、天然气及天然气凝析液的勘探、开发与生产业务，主打低成本陆上储备开发，为北美市场供应稳定能源产品。
PCRX vs REPX — 直观对比
营收规模更大
PCRX
是对方的1.6倍
$113.9M
营收增速更快
REPX
高出6.1%
5.0%
净利率更高
PCRX
高出63.5%
-61.8%
两年增速更快
REPX
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $113.9M |
| 净利润 | $2.9M | $-70.4M |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | 38.3% |
| 净利率 | 1.6% | -61.8% |
| 营收同比 | 5.0% | 11.2% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.07 | $-3.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXREPX
| Q1 26 | $177.4M | $113.9M | ||
| Q4 25 | $196.9M | $97.3M | ||
| Q3 25 | $179.5M | $106.9M | ||
| Q2 25 | $181.1M | $85.4M | ||
| Q1 25 | $168.9M | $102.5M | ||
| Q4 24 | $187.3M | $102.7M | ||
| Q3 24 | $168.6M | $102.3M | ||
| Q2 24 | $178.0M | $105.4M |
净利润PCRXREPX
| Q1 26 | $2.9M | $-70.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $16.3M | ||
| Q2 25 | $-4.8M | $30.5M | ||
| Q1 25 | $4.8M | $28.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $25.7M | ||
| Q2 24 | $18.9M | $33.5M |
毛利率PCRXREPX
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
营业利润率PCRXREPX
| Q1 26 | 3.9% | 38.3% | ||
| Q4 25 | 1.2% | 26.9% | ||
| Q3 25 | 3.5% | 27.0% | ||
| Q2 25 | 4.7% | 33.7% | ||
| Q1 25 | 1.2% | 48.3% | ||
| Q4 24 | 13.2% | 31.2% | ||
| Q3 24 | -82.8% | 17.1% | ||
| Q2 24 | 15.9% | 50.9% |
净利率PCRXREPX
| Q1 26 | 1.6% | -61.8% | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | 15.3% | ||
| Q2 25 | -2.7% | 35.7% | ||
| Q1 25 | 2.8% | 27.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 25.1% | ||
| Q2 24 | 10.6% | 31.8% |
每股收益（稀释后）PCRXREPX
| Q1 26 | $0.07 | $-3.38 | ||
| Q4 25 | $0.05 | $4.02 | ||
| Q3 25 | $0.12 | $0.77 | ||
| Q2 25 | $-0.11 | $1.44 | ||
| Q1 25 | $0.10 | $1.36 | ||
| Q4 24 | $0.38 | $0.52 | ||
| Q3 24 | $-3.11 | $1.21 | ||
| Q2 24 | $0.39 | $1.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | — |
| 总债务越低越好 | — | $240.7M |
| 股东权益账面价值 | $653.9M | $553.4M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.43× |
8季度趋势，按日历期对齐
现金及短期投资PCRXREPX
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
总债务PCRXREPX
| Q1 26 | — | $240.7M | ||
| Q4 25 | $372.2M | $247.9M | ||
| Q3 25 | $376.7M | $367.0M | ||
| Q2 25 | $580.5M | $275.2M | ||
| Q1 25 | $583.4M | $249.3M | ||
| Q4 24 | $585.3M | $269.5M | ||
| Q3 24 | — | $288.6M | ||
| Q2 24 | — | $322.7M |
股东权益PCRXREPX
| Q1 26 | $653.9M | $553.4M | ||
| Q4 25 | $693.1M | $634.2M | ||
| Q3 25 | $727.2M | $566.5M | ||
| Q2 25 | $757.8M | $556.9M | ||
| Q1 25 | $798.5M | $532.4M | ||
| Q4 24 | $778.3M | $510.6M | ||
| Q3 24 | $749.6M | $507.4M | ||
| Q2 24 | $879.3M | $489.0M |
总资产PCRXREPX
| Q1 26 | $1.2B | $1.2B | ||
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.5B | $1.0B | ||
| Q1 25 | $1.6B | $994.9M | ||
| Q4 24 | $1.6B | $993.5M | ||
| Q3 24 | $1.5B | $997.9M | ||
| Q2 24 | $1.6B | $1.0B |
负债/权益比PCRXREPX
| Q1 26 | — | 0.43× | ||
| Q4 25 | 0.54× | 0.39× | ||
| Q3 25 | 0.52× | 0.65× | ||
| Q2 25 | 0.77× | 0.49× | ||
| Q1 25 | 0.73× | 0.47× | ||
| Q4 24 | 0.75× | 0.53× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.66× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $47.2M |
| 自由现金流经营现金流 - 资本支出 | — | $24.6M |
| 自由现金流率自由现金流/营收 | — | 21.6% |
| 资本支出强度资本支出/营收 | — | 41.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PCRXREPX
| Q1 26 | — | $47.2M | ||
| Q4 25 | $43.7M | $64.9M | ||
| Q3 25 | $60.8M | $63.6M | ||
| Q2 25 | $12.0M | $33.6M | ||
| Q1 25 | $35.5M | $50.4M | ||
| Q4 24 | $33.1M | $66.4M | ||
| Q3 24 | $53.9M | $72.1M | ||
| Q2 24 | $53.2M | $51.6M |
自由现金流PCRXREPX
| Q1 26 | — | $24.6M | ||
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | — | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | — | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | — | ||
| Q2 24 | $51.6M | — |
自由现金流率PCRXREPX
| Q1 26 | — | 21.6% | ||
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 29.0% | — |
资本支出强度PCRXREPX
| Q1 26 | — | 41.3% | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 0.9% | — |
现金转化率PCRXREPX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 3.90× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | 7.37× | 1.76× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.81× | ||
| Q2 24 | 2.82× | 1.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
REPX
暂无分部数据
